We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

139 hedge funds and large institutions have $1.03B invested in Arcus Biosciences in 2020 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 48 increasing their positions, 24 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

421% more call options, than puts

Call options by funds: $3.44M | Put options by funds: $661K

392% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 12

176% more capital invested

Capital invested by funds: $375M → $1.03B (+$660M)

100% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 24

51% more funds holding

Funds holding: 92 → 139 (+47)

14.61% more ownership

Funds ownership: 58.73% → 73.34% (+15%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
139
Holders Change
+47
Holders Change %
+51.09%
% of All Funds
2.85%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
59
Increased
48
Reduced
24
Closed
12
Calls
$3.44M
Puts
$661K
Net Calls
+$2.78M
Net Calls Change
+$2.79M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$70.9M
2
BI
BVF Inc
California
+$49.8M
3
EC
EcoR1 Capital
California
+$41M
4
FCM
Farallon Capital Management
California
+$27M
5
State Street
State Street
Massachusetts
+$25.5M

Top Sellers

1
PS
Peter Svennilson
-$47.9M
2
BC
Boxer Capital
California
-$27M
3
Verition Fund Management
Verition Fund Management
Connecticut
-$6.35M
4
ACM
Aisling Capital Management
New York
-$4.63M
5
HA
HHLR Advisors
Cayman Islands
-$3.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
Marshall Wace
151
Marshall Wace
United Kingdom
– -$35K -2,549 Closed
3 4 5 6
7

RCUS Hedge Fund Activity: Q2 2020 in Review

139 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2020, worth a combined $1.03B — up 176% from $375M a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new RCUS positions and 12 closed out — a net gain of 47 holders — while 48 added to existing stakes and 24 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $70.9M. The largest seller was Peter Svennilson, cutting an estimated $47.9M.

  • 139 institutional investors held Arcus Biosciences (RCUS) as of Q2 2020, up from 92 in Q1 2020.
  • Funds reported $1.03B of Arcus Biosciences stock for Q2 2020, up 176% quarter-over-quarter.
  • 59 funds opened new Arcus Biosciences positions in Q2 2020 and 12 closed out, a net change of +47 holders.
  • The largest Arcus Biosciences buyer in Q2 2020 was Fidelity Investments, an estimated $70.9M added.
  • The largest Arcus Biosciences seller in Q2 2020 was Peter Svennilson, an estimated $47.9M sold.

Based on aggregated 13F filings for Q2 2020.